Microbix Biosystems, Sequel Pharma Finalize Kinlytic Production Agreement

Microbix Biosystems Inc. and its commercialization partner, Sequel Pharma, LLC, have signed an agreement with a leading international contract development and manufacturing organization to produce Kinlytic® urokinase, a biologic drug used to dissolve blood clots. This partnership is aimed at advancing the production and packaging of the drug for broader distribution and clinical use.